Skip to main content

Find Clinical Trials

Home
Conditions
Leukemia, Hairy Cell

Clinical trial condition

Leukemia, Hairy Cell

Explore clinical trials studying Leukemia, Hairy Cell. Study availability and eligibility vary by location and protocol.

170 public trials 16 recruiting studies

Refine in advanced search Browse all conditions

Leukemia, Hairy Cell trial results

Completed

LMB-2 to Treat Hairy Cell Leukemia

NCT00321555

Conditions: Hairy Cell Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States

View Trial Details

Completed

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

NCT00611351

Conditions: Blast Crisis, Blood Protein Disorders, Bone Marrow Diseases, +64 more
Locations: Unversity of Nebraska Medical Center Omaha, Nebraska, United States

View Trial Details

Completed

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

NCT02034110

Conditions: Biliary Tract Diseases, Biliary Tract Neoplasms, Blood Protein Disorders, +35 more
Locations: Novartis Investigative Site Little Rock, Arkansas, United States

Novartis Investigative Site Santa Monica, California, United States

Novartis Investigative Site Bethesda, Maryland, United States

Novartis Investigative Site Boston, Massachusetts, United States

View all 41 locations

View Trial Details

Completed

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

NCT03010358

Conditions: Anemia, B-Cell Prolymphocytic Leukemia, Chronic Disease, +36 more
Locations: OHSU Knight Cancer Institute Portland, Oregon, United States

View Trial Details

Completed

Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

NCT00897767

Conditions: Blast Crisis, Bone Marrow Diseases, Carcinogenesis, +42 more
Locations: UAB Comprehensive Cancer Center Birmingham, Alabama, United States

Mayo Clinic Scottsdale Scottsdale, Arizona, United States

Aurora Presbyterian Hospital Aurora, Colorado, United States

Boulder Community Hospital Boulder, Colorado, United States

View all 214 locations

View Trial Details

Completed

Bioavailability Study of 300 mg Trazodone Hydrochloride (New Polymer) vs. 300 mg Trazodone Hydrochloride (Contramid® Prolonged-release Tablets) Under Fasting Conditions

NCT05136521

Conditions: Healthy, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations: CROSS Research S.A., Phase I Unit, Via F.A. Giorgioli 14 Phone: Fax: +41.91.63.00.511 Email: Arzo, Switzerland

View Trial Details

Completed

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

NCT00424242

Conditions: Amyloidosis, Blast Crisis, Blood Coagulation Disorders, +112 more
Locations: Robert H. Lurie Comprehensive Cancer Center at Northwestern University Chicago, Illinois, United States

View Trial Details

Completed

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

NCT02037256

Conditions: Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Blood Protein Disorders, +130 more
Locations: Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States

View Trial Details

Completed

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

NCT00489203

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, +207 more
Locations: Hackensack University Medical Center Hackensack, New Jersey, United States

Fred Hutchinson Cancer Research Center Seattle, Washington, United States

View Trial Details

Completed

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

NCT01258998

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, +82 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details